Murray Brand, DO
Family Medicine · Philadelphia, PANPI 1124061221
Payments from drug & device makers
Across 194 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$616
- GSK$614
- Amarin Pharma, Inc.$295
- Boehringer Ingelheim$288
- Pfizer$254
- Daiichi Sankyo Inc.$210
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,85499%
- Education$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $616 |
| GSK | 32 | $614 |
| Amarin Pharma, Inc. | 8 | $295 |
| Boehringer Ingelheim | 18 | $288 |
| Pfizer | 20 | $254 |
| Daiichi Sankyo Inc. | 6 | $210 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $199 |
| Amgen | 5 | $184 |
| Novo Nordisk | 12 | $165 |
| E.r. Squibb & Sons, L.L.C. | 3 | $134 |
| Merck | 11 | $127 |
| AbbVie(2 entities) | 6 | $104 |
| Novartis | 5 | $67 |
| Sanofi Pasteur Inc. | 5 | $64 |
| Astellas Pharma US Inc | 3 | $51 |
| Supernus Pharmaceuticals, Inc. | 4 | $47 |
| Gilead | 3 | $47 |
| Kvk-tech, Inc. | 1 | $45 |
| Indivior Inc. | 2 | $41 |
| Kowa Pharmaceuticals America, Inc. | 3 | $40 |
| Hikma Pharmaceuticals USA | 2 | $35 |
| Agios Pharmaceuticals, Inc. | 1 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Lilly USA, LLC | 2 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| Abbott | 1 | $24 |
| Shire North American Group Inc | 1 | $17 |
| Mylan Specialty L.p. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Seqirus USA Inc | 1 | $14 |
| Assertio Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,893 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 138 | $138,266 |
| OzempicSemaglutide | 73 | $91,518 |
| TrulicityDulaglutide | 74 | $88,837 |
| JardianceEmpagliflozin | 95 | $81,789 |
| FarxigaDapagliflozin Propanediol | 79 | $74,679 |
| XareltoRivaroxaban | 29 | $45,507 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 316 | $44,074 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 61 | $39,375 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $37,585 |
| XifaxanRifaximin | 11 | $35,852 |
| MyrbetriqMirabegron | 49 | $34,786 |
| JanumetSitagliptin Phos/Metformin Hcl | 25 | $25,394 |
| Bydureon BciseExenatide Microspheres | 18 | $23,694 |
| VascepaIcosapent Ethyl | 44 | $22,407 |
| JanuviaSitagliptin Phosphate | 31 | $21,718 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $254 | $138,266138 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $288 | $91,645114 claims |
| Novo NordiskOzempic | $165 | $91,51873 claims |
| Lilly USA, LLCTrulicity | $26 | $88,83774 claims |
| AstraZenecaFarxiga | $616 | $74,67979 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $614 | $64,51082 claims |
| MerckJanumet, Januvia | $127 | $47,11256 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $35 | $44,074316 claims |
| Indivior Inc.Suboxone | $41 | $39,37561 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $199 | $35,85211 claims |
| Astellas Pharma US IncMyrbetriq | $51 | $34,78649 claims |
| AbbVieCreon | $104 | $18,48715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Philadelphia
- Daniel LinPhiladelphia$392K
- Glenn RosenPhiladelphia$367K
- Christopher ChambersPhiladelphia$350K
- Deborah WittPhiladelphia$226K
- Michael AttanasioPhiladelphia$214K
- Jonah MinkPhiladelphia$145K
- Celia EzidiegwuPhiladelphia$118K
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.